Intersect ENT Insiders
XENTDelisted Stock | USD 28.24 0.00 0.00% |
Intersect ENT employs about 406 people. The company is managed by 20 executives with a total tenure of roughly 201 years, averaging almost 10.0 years of service per executive, having 20.3 employees per reported executive. Breaking down Intersect ENT's management performance can provide insight into the firm performance.
Lisa Earnhardt CEO CEO and President and Director |
Thomas West CEO President CEO, Director |
Intersect |
Intersect ENT Management Team Effectiveness
The company has return on total asset (ROA) of (17.82) % which means that it has lost $17.82 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (181.73) %, meaning that it created substantial loss on money invested by shareholders. Intersect ENT's management efficiency ratios could be used to measure how well Intersect ENT manages its routine affairs as well as how well it operates its assets and liabilities.Intersect ENT Workforce Comparison
Intersect ENT is rated first in number of employees category among related companies. The total workforce of Medical Devices industry is at this time estimated at about 133,217. Intersect ENT adds roughly 406 in number of employees claiming only tiny portion of all equities under Medical Devices industry.
The company has Profit Margin (PM) of (85.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (54.81) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $54.81. Intersect ENT Notable Stakeholders
An Intersect ENT stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intersect ENT often face trade-offs trying to please all of them. Intersect ENT's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intersect ENT's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lisa Earnhardt | CEO and President and Director | Profile | |
Thomas West | President CEO, Director | Profile | |
James Stambaugh | Vice President of Clinical and Reimbursement | Profile | |
Amy Wolbeck | Vice President of Regulatory Affairs and Quality | Profile | |
Jeryl Hilleman | CFO | Profile | |
Christine Kowalski | COO | Profile | |
Richard Kaufman | COO and Sr. VP | Profile | |
William Vernon | Director | Profile | |
Casey Tansey | Independent Director | Profile | |
Dana Mead | Independent Director | Profile | |
Frederic Moll | Independent Director | Profile | |
Kieran Gallahue | Lead Director | Profile | |
Cynthia Lucchese | Independent Director | Profile | |
Teresa Kline | Director | Profile | |
David Lehman | General Counsel | Profile | |
Drake Parker | Advisor – Strategic Initiatives | Profile | |
Robert Binney | Chief Commercial Officer | Profile | |
Susan Stimson | Chief Strategy Officer | Profile | |
Gwen Carscadden | Chief People Officer | Profile | |
Chas McKhann | Chief Commercial Officer | Profile |
About Intersect ENT Management Performance
The success or failure of an entity such as Intersect ENT often depends on how effective the management is. Intersect ENT management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intersect management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intersect management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Intersect ENT, Inc. operates as an ear, nose, and throat medical technology company in the United States. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. Intersect Ent operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 406 people.
The data published in Intersect ENT's official financial statements usually reflect Intersect ENT's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Intersect ENT. For example, before you start analyzing numbers published by Intersect accountants, it's critical to develop an understanding of what Intersect ENT's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Intersect ENT's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intersect ENT's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Intersect ENT's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intersect ENT. Please utilize our Beneish M Score to check the likelihood of Intersect ENT's management manipulating its earnings.
Intersect ENT Workforce Analysis
Traditionally, organizations such as Intersect ENT use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intersect ENT within its industry.Intersect ENT Manpower Efficiency
Return on Intersect ENT Manpower
Revenue Per Employee | 256.9K | |
Revenue Per Executive | 5.2M | |
Net Loss Per Employee | 218.4K | |
Net Loss Per Executive | 4.4M | |
Working Capital Per Employee | 315.6K | |
Working Capital Per Executive | 6.4M |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Intersect Stock
If you are still planning to invest in Intersect ENT check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intersect ENT's history and understand the potential risks before investing.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |